Navigation Links
China Sky One Medical, Inc. Passes First Phase Examination for (CE) Certification
Date:9/19/2008

HARBIN, China, Sept. 19 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that it has successfully completed the first phase of examinations for the Conformite Europeenne (CE) certification, or CE mark, which indicates that a company's products have met rigorous testing and safety standards and are approved for sale within the European Union (EU).

In order to sell products throughout the EU, China Sky one submitted an application for CE certification in May, 2008, to Heilongjiang Import-Export Commodities Inspection and Quarantine (SAIECIQ) Bureau Technology Center, the CE certification's agency in China. Experts from the center spent three months reviewing and examining manufacturing materials, on-site facilities, and product samples. It was determined that China Sky One Medical's facilities, quality control systems, and products met CE certification standards. The Company is currently working on the second phase of the CE certification examination and estimates that it could begin to export products to the EU with the CE mark starting in 2008. (For more information visit http://www.cemarking.net )

"Receiving the CE certification will be a passport to importing our drugs into the EU market and also attest to the high quality of our products and our manufacturing standards," said Mr. Yan-qing Liu, Chairman, CEO and President of China Sky One Medical. "Affixing the CE mark to our products will ensure that they meet all of the applicable regulatory and safety requirements within the EU."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio- Engineering Company Limited, and Heilongjiang Tianlong Pharmaceutical, Inc., the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

For more information, please contact:

Company Contact:

China Sky One Medical, Inc.

Mr. Yu-bo Hao, Board Secretary

Tel: +86-0451-5399-4069

Email: china_sky_one@yahoo.cn

Investor Relations Contact:

CCG Investor Relations

Mr. Crocker Coulson, President

Tel: +1-646-213-1915

Email: crocker.coulson@ccgir.com

Mr. Richard Micchelli, Financial Writer

Tel: +1-646-454-4516

Email: richard.micchelli@ccgir.com

Web: http://www.ccgir.com


'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Pharma Holdings, Inc. Projects 3rd Quarter 2008 Revenue Growth to Exceed 40%
2. China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII
3. China Biopharma Effects 1 for 100 Reverse Stock Split
4. China Sky One Medical, Inc. Completes Acquisition of Peng Lai Jin Chuang Company
5. China Yingxia International, Inc. Appoints New Vice President of Finance
6. China-Biotics, Inc. Provides Update on Construction of New Manufacturing Facility
7. China Biologic Products to Present at the SIG Beijing Management Summit
8. China Biologics Production Facility Renews GMP Certification
9. China Bio Energy Holdings Group Announces Participation in the Susquehanna Second Annual Beijing Management Summit
10. Plexus Announces Expansion in Hangzhou, China
11. China Sky One Medical, Inc. Approved to List on the NASDAQ Global Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a ... take place between the two entities said Poloz. ... Ottawa , he pointed to the country,s ... the federal government. ... said, "Both institutions have common economic goals, why not sit ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):